SDMHF News and Press, Sartorius Stedim Biotech From 04/21/22

First-quarter results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 27.6 percent in constant currencies, underlying EBITDA margin 35.2 percent Healthy demand situation; normalization of pandemic-related effects and development of order int...

Sartorius Stedim Biotech presents annual report for 2021 PR Newswire AUBAGNE, France , Feb. 17, 2022 /PRNewswire/ -- Sartorius Stedim Biotech, a leading partner of the biopharma industry, today has presented its Universal Registration Document 2021 including th...

Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 1.26 euros per share to Annual Shareholders' Meeting PR Newswire AUBAGNE, France , Feb. 9, 2022 /PRNewswire/ -- The Board of Directors of Sartorius Stedim Biotech S.A. resolved at toda...

Sartorius Stedim Biotech completes acquisition of Novasep's chromatography division PR Newswire - Sales revenue forecast for 2022 updated due to acquisition AUBAGNE, France , Feb. 8, 2022 /PRNewswire/ -- Sartorius Stedim Biotech, a leading partner of the ...

Preliminary results 2021 of Sartorius Stedim Biotech - Sales revenue up 52.6 percent to 2,887 million euros; underlying EBITDA margin at 35.8 percent, up from 31.7 percent a year ago - Dynamic and profitable organic growth; pandemic-related demand as well as excellent develo...

Nine-month results of Sartorius Stedim Biotech - Sales revenue up 56.2 percent to 2,109 million euros; underlying EBITDA margin 36.3 percent - Dynamic and profitable organic growth; significant demand momentum generated by the production of coronavirus vaccines as well as st...

Founded in 1870, Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. The company is a leading international backend partner for the biopharmaceutical industry and laboratories. Sartorius Stedim is partnering with McMaster University for advanced research in biomanufactu...

McMaster, Sartorius Stedim Biotech team up to advance biomanufacturing processes with next-gen tech PR Newswire HAMILTON, ON and AUBAGNE, France , Aug. 23, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical...

The life science company Sartorius (OTCPK:SARTF), through its subgroup Sartorius Stedim Biotech (OTCPK:SDMHF), acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany. Xell AG develops, produces, and markets media and feed supplements for cell cultures, especially for man...

Sartorius Stedim Biotech acquires cell culture specialist Xell AG - Extension of the Sartorius Stedim Biotech cell culture media business with a focus on media for gene therapeutics and vaccines - Significant expansion of capacities for manufacturing dry powder and liquid me...